All PlansPrior AuthHigh impact
Omalizumab Products: Omalizumab (Xolair®); Omalizumab-igec (Omlyclo®)
BCBS Tennessee·TN · Allergy & Immunology, Pulmonology, ENT (Ear, Nose & Throat) +3 more·Medical Policy
Effective date
Dec 1, 2026
We identified it
Sep 10, 2026
Summary
This is a new medical policy for Omalizumab products (Xolair® and Omlyclo®) covering four FDA-approved indications (asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria) plus two compendial uses. The policy establishes specific prior authorization requirements, documentation standards, prescriber specialty requirements, and coverage criteria for each indication. Implementation is not required until December 1, 2026.
Action Required
By November 15, 2026: Billing and prior authorization teams must review this policy in detail and prepare implementation. By December 1, 2026: (1) Update billing system to require prior authorization for all Omalizumab prescriptions with indication-specific criteria; (2) Create or update prior authorization request forms to include all required documentation elements for each indication (IgE levels, previous medication trials, specialty confirmation, clinical scores where applicable); (3) Configure system alerts to verify prescriber specialty matches the indication (allergist/immunologist for asthma/food allergy/urticaria, otolaryngologist for CRSwNP, oncologist/dermatologist/hematologist for checkpoint inhibitor toxicity, etc.); (4) Train prior authorization staff on the four covered indications and two compendial uses, including age restrictions and specific approval criteria for each; (5) Update claim submission procedures to ensure claims include required prior authorization before processing. Failure to implement prior authorization requirements will result in claim denials for non-compliant submissions.